RxDoctor Payments Data

Jane Chu

Family · Los Angeles, CANPI 1700184249

Payments from drug & device makers

$4,340in general payments, 2019–2025

Across 178 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$675
  • Johnson & Johnson$652
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$518
  • AstraZeneca$347
  • Jazz Pharmaceuticals Inc.$291
  • Boehringer Ingelheim$279
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,340 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$42,083
EliquisApixaban17$19,466
MounjaroTirzepatide19$19,396
TrulicityDulaglutide20$18,397
JanumetSitagliptin Phos/Metformin Hcl16$15,330
XareltoRivaroxaban16$15,259
Lidocaine16$3,161
Albuterol Sulfate HfaAlbuterol Sulfate20$1,410
Gabapentin59$1,209
Nateglinide12$946
Atorvastatin Calcium92$795
Mirtazapine20$780
Levothyroxine Sodium28$625
Valsartan13$492
Rosuvastatin Calcium50$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$110$42,08339 claims
Lilly USA, LLCMounjaro, Trulicity$239$37,79339 claims
Johnson & JohnsonXarelto$652$15,25916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →